South Korea-based Hanmi Pharmaceutical has reported positive outcomes from a Phase I/II clinical trial of Tivumecirnon ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Health Canada has approved MSD's anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating adults with ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Merck & Co.'s heavy reliance on its cancer drug Keytruda, which accounts for nearly half of the company's revenue, is raising investor concerns as the drug's patent expiration approaches in 2028 ...

The entertainment company plans to add more live ESPN shows to its main streaming service, saying customers want simplicity. The company's shares rose as investors breathed a sigh of relief on strong ...

Cigna recorded more high-cost claims due to increased usage of specialty medications such Merck's (MRK.N), opens new tab blockbuster cancer therapy Keytruda and other inpatient surgeries like ...

The aim of the data-powered offering is to identify consumers who are predicted to be in the market for a brand’s product or service within the next three months. Marketers can use Brand+ to ...

Results have been announced from a Phase III trial of Merck & Co’s (NYSE: MRK) anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima (lenvatinib), Eisai’s (TYO: 4523) orally available multiple ...

Phase III CheckMate -8HW trial shows the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly improved progression-free survival and overall response rates in patients with ...